COVID-19 Current Therapy Market Expansion Is Opening New Pathways For Strategic Investment
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
COVID-19 Current Therapy Market Growth Potential: How Will Market Size Change Through 2030?
The market for COVID-19 therapies has experienced a sharp contraction over recent years, with projections indicating a decrease from $2.35 billion in 2025 to $1.57 billion in 2026, representing a compound annual growth rate (CAGR) of -33.2%. This downturn in the historical period is largely explained by the abrupt emergence of the pandemic, elevated rates of hospitalization, a scarcity of available treatment options in the early stages, a reduction in both governmental and healthcare-related efforts, and a diminished number of emergency approvals granted for pharmaceutical interventions.
The market size for current COVID-19 therapies is projected to undergo a sharp contraction over the coming years, reaching $0.31 billion by 2030 with a compound annual growth rate (CAGR) of -33.2%. This downturn during the forecast period is largely driven by reduced telemedicine adoption for managing COVID-19 and a slower expansion of home care services. Key developments anticipated in this period include a growing reliance on antiviral and monoclonal antibody treatments, a heightened use of corticosteroids for severe infections, an increase in home care and remote patient monitoring, an expansion of supplement and immune support options, and the integration of combination and experimental therapies into standard protocols.
Download A Free Sample Report For Comprehensive Market Insights:
COVID-19 Current Therapy Market Expansion Drivers: What Is Shaping Future Growth?
The growth of the COVID-19 current therapy market is anticipated to be driven forward by the ongoing expansion of healthcare infrastructure. Within the healthcare industry, various sectors of the economic system are brought together and integrated to provide products and services focused on curing, preventing, rehabilitating, and delivering palliative care to patients. Effective implementation of COVID-19 therapies relies heavily on robust healthcare infrastructure, as it facilitates timely patient care, supports clinical trials and research, and supplies the essential resources needed for optimal treatment delivery. For example, data from the American Health Care Association, a nonprofit organization based in the US, reveals that the number of hospitals in the country grew to 6,129 in May 2023, up from 6,093 the previous year. Additionally, a May 2023 report from the Office for National Statistics, a UK government department, indicated that healthcare spending in the United Kingdom experienced a notable increase of 9.4% in nominal terms and 9.7% in real terms. Consequently, the expansion of the healthcare industry is fueling the growth of the COVID-19 current therapy market.
COVID-19 Current Therapy Market Segment Landscape: Which Areas Lead Market Development?
The covid-19 current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others
Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal Agents
COVID-19 Current Therapy Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Major players within the current COVID-19 therapeutic market are placing a heightened emphasis on developing cutting-edge offerings—specifically oral antiviral drugs for COVID-19—to secure a stronger competitive position. Antiviral therapy encompasses the administration of pharmaceutical agents formulated to suppress viral replication and curb the spread of viruses throughout an organism. As an example, in April 2024, Invivyd—a U.S.-based organization committed to creating antibody-based treatments for tackling severe viral diseases—provided an update regarding the release of PEMGARDA™. After receiving emergency use authorization from the U.S. Food and Drug Administration (FDA), PEMGARDA was swiftly made accessible for commercial purposes. This therapeutic product is designed to prevent COVID-19 among individuals who are moderately to severely immunocompromised.
COVID-19 Current Therapy Market Industry Leaders And Market Competition
Major companies operating in the covid-19 current therapy market are Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, Thermo Fisher Scientific
Access The Complete COVID-19 Current Therapy Market Report:
COVID-19 Current Therapy Market Geographic Distribution And Regional Opportunities
North America is the largest region in the COVID-19 current therapy market in 2025. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the covid-19 current therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
